Gannett Co., Inc.
Extract: Poison Pill Activity: Exemption/Carveout/Waiver Announcement from a 8-K on 11/22/2022   Download
SEC Document
SEC Filing
As of November 21, 2022, the board of directors of Gannett Co., Inc. (the “Company”), granted an exemption to an investor and its related funds (the “Investor”) from certain provisions of the Company’s Section 382 Rights Agreement (the “Rights Agreement”), dated as of April 6, 2020, and determined that such Investor is an Exempt Person and the Rights become exercisable if the Investor acquires more than 9.99% of the outstanding common shares prior to the expiration of the Rights Agreement. Terms used herein and not otherwise defined have the meanings given them in the Rights Agreement.

This Current Report on Form 8-K is being furnished pursuant to Regulation FD. The information furnished pursuant to this Current Report on Form 8-K shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth by specific reference in such filing that such information is to be considered “filed” or incorporated by reference therein.